Adaptive Biotechnologies Corp

Company Profile

• Business description

  Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

• Contact

  1165 Eastlake Avenue East
  SeattleWA98109
  USA

  T: +1 206 659-0067

  https://www.adaptivebiotech.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Diagnostics & Research

  Fiscal Year End

  31 December 2026

  Employees

  624